Deutsche Bank Downgrades MAP Pharmaceuticals (MAPP) to Hold; Doesn't Expect Other Bids
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Canaccord Genuity Downgrades MAP Pharmaceuticals (MAPP) to Hold
January 24, 2013 8:43 AM ESTCanaccord Genuity downgraded MAP Pharmaceuticals (NASDAQ: MAPP) from Buy to Hold with a price target of $25 on of Allergan takeover.
"Were still surprised by the timing though more may be known when filings come out. At this point we think the... More
Leerink Swann Downgrades MAP Pharmaceuticals (MAPP) to Market Perform
January 24, 2013 6:54 AM ESTLeerink Swann downgraded MAP Pharmaceuticals (NASDAQ: MAPP) from Outperform to Market Perform with a price target of $25.00 (from $19.00) following yesterday's takeover deal.
"We believe MAPP's $25/share takeout valuation is fair and includes some of the technology value in MAPP's Tempo inhaler device... More
